Neurotronic, Inc., a U.S.-based medical technology company developing multi-organ denervation therapies for cardiovascular and metabolic diseases, announced upcoming presentations of the first clinical outcomes from its Neuviant™ Multi-organ Denervation (MDN) system.
The results will be shared at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 meeting in San Francisco and represent the first reported human data on a therapy designed to modulate multiple overactive sympathetic pathways — commonly linked to type 2 diabetes mellitus (T2DM) and hypertension (HTN).
Findings from the NECTAR III and NECTAR IV clinical studies evaluated the safety, performance, and efficacy of hepatic and bilateral renal denervation using Neurotronic’s investigational Neuviant MDN System. The single-arm studies enrolled patients with both T2DM and HTN, including those whose conditions remained uncontrolled despite medication.
The data will be presented by Professor Dr. Horst Sievert, Director of CardioVascular Center Frankfurt, and Dr. Ajay J. Kirtane, Director of Columbia Interventional Cardiovascular Care at Columbia University Medical Center, during two sessions on October 26 and 27.
The Neuviant MDN procedure delivers dehydrated ethanol via catheter to the tissue surrounding the hepatic and renal arteries. The approach is designed to disrupt overactive sympathetic nerve signaling, with the aim of reducing both elevated blood sugar and high blood pressure.
The presentations are scheduled as follows:
- Title: Multi-organ Arterial Denervation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR IV Trial)
Presenter: Prof. Dr. Horst Sievert
Session: Best Endovascular Intervention Abstracts
Date/Time: Sunday, October 26, 2025, 12:10–12:20 p.m.
Location: Station 8, Halls B–C, Moscone South - Title: Multi-organ Ethanol Denervation to Treat Type 2 Diabetes Mellitus and Hypertension: 6-Month Results of an Early Feasibility Study
Presenter: Dr. Ajay J. Kirtane
Session: Innovation Session 7: Percutaneous Denervation for the Treatment of Chronic Diseases
Date/Time: Monday, October 27, 2025, 7:49–8:00 a.m.
Location: Innovation Theater, Hall E, Moscone North
The Neuviant MDN System, which combines the Neuviant MDN Catheter and the ethanol-based agent Simpathol™, remains investigational and is currently being studied as a treatment for T2DM and HTN.
Founded in 2015, Neurotronic, Inc. develops multi-organ denervation therapies targeting sympathetic overactivity implicated in chronic cardiovascular and metabolic diseases.
